Results from a randomized placebo-controlled clinical trial of a RBX2660-a microbiota-based drug for the prevention of recurrent Clostridium difficile infection
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background: Despite advancements, recurrent Clostridium difficile infections (CDI) remain an urgent public health threat with insufficient response rates to currently approved antibiotic therapies. Microbiota-based treatments appear effective, but rigorous clinical trials are required to optimize dosing strategies and substantiate long-term safety. Methods: This randomized, double-blind, placebo-controlled phase 2B trial enrolled adults with 2 or more CDI recurrences to receive: 2 doses of RBX2660, a standardized microbiota-based drug (group A); 2doses of placebo (group B); or 1 dose of RBX2660 followed by 1 dose of placebo (group C). Efficacy was defined as prevention of recurrent CDI for 8 weeks following treatment. Participants who had a recurrence within 8 weeks were eligible to receive up to 2 open-label RBX2660 doses. The primary endpoint was efficacy for group A compared to group B. Secondary endpoints included the efficacy of group C compared to group B, combined efficacy in the blinded and open-label phases, and safety for 24 months. Results: The efficacy for groups A, B, and C were 61%, 45%, and 67%, respectively. The primary endpoint was not met (P = .152). One RBX2660 dose (group C) was superior to placebo (group B; P = .048), and the overall efficacy (including open-label response) for RBX2660-treated participants was 88.8%. Adverse events did not differ significantly among treatment groups. Conclusions: One, but not 2, doses of RBX2660 was superior to placebo in this randomized, placebo-controlled trial. These data provide important insights for a larger phase 3 trial and continued clinical development of RBX2660. Clinical Trials Registration: NCT02299570.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the efficacy of retention enema had been once doubted, Orenstein and Dubberke et al. have proven it more efficient and safe than placebo in phase I and phase II recurrent CDI clinical trials.64,65”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationMicrobiota-mediated colonization resistance against intestinal pathogens
Buffie, C. G., & Pamer, E. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3535 · Cited by 1,564
Clostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Gough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Self-citationBezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1602615 · Cited by 858
Self-citation
Cited by
Antibiotic resistance: a rundown of a global crisis
Aslam, B., Wang, W., Arshad, M. I., Khurshid, M., Muzammil, S., Rasool, M. H., Nisar, M. A., Alvi, R. F., Aslam, M. A., Qamar, M. U., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s173867 · Cited by 2,552
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Sorbara, M. T., & Pamer, E. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00667-9 · Cited by 468
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
Khanna, S., Assi, M., Lee, C., Yoho, D., Louie, T., Knapple, W., Aguilar, H., Garcia-Diaz, J., Wang, G. P., Berry, S. M., et al. (2022) · Drugs · doi:10.1007/s40265-022-01797-x · Cited by 301
“In this prior study, one and two doses of RBX2660 administered 1 week apart were assessed [8].”
MethodSelf-citationPeery, A. F., Kelly, C. R., Kao, D., Vaughn, B. P., Lebwohl, B., Singh, S., Imdad, A., & Altayar, O. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.008 · Cited by 258
Bella, S. D., Sanson, G., Monticelli, J., Zerbato, V., Principe, L., Giuffrè, M., Pipitone, G., & Luzzati, R. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00135-23 · Cited by 228
Minkoff, N. Z., Aslam, S., Medina, M., Tanner‐Smith, E. E., Zackular, J. P., Acra, S. A., Nicholson, M. R., & Imdad, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013871.pub2 · Cited by 205
Clostridioides difficile: diagnosis and treatments
Guery, B., Galperine, T., & Barbut, F. (2019) · BMJ · doi:10.1136/bmj.l4609 · Cited by 106
McGovern, B. H., Ford, C. B., Henn, M. R., Pardi, D. S., Khanna, S., Hohmann, E. L., O’Brien, E. J., Desjardins, C. A., Bernardo, P., Wortman, J. R., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa387 · Cited by 159
Self-citationYadegar, A., Pakpour, S., Ibrahim, F. F., Nabavi-Rad, A., Cook, L., Walter, J., Seekatz, A. M., Wong, K., Monaghan, T. M., & Kao, D. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.03.019 · Cited by 85
Langdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C. D., Dubberke, E. R., & Dantas, G. A. (2021) · Genome Medicine · doi:10.1186/s13073-021-00843-9 · Cited by 93
Self-citationFecal Microbiota Transplantation in Inflammatory Bowel Disease
Boicean, A., Bîrluțiu, V., Ichim, C., Anderco, P., & Bîrsan, S. (2023) · Biomedicines · doi:10.3390/biomedicines11041016 · Cited by 93
The microbiome and host mucosal interactions in urinary tract diseases
Jones, B., Chonwerawong, M., Marcelino, V. R., Deshpande, A., Forster, S. C., & Starkey, M. R. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-00372-5 · Cited by 90
Orenstein, R., Dubberke, E. R., Khanna, S., Lee, C., Yoho, D. S., Johnson, S., Hecht, G. A., DuPont, H. L., Gerding, D. N., Blount, K., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07256-y · Cited by 90
Self-citationSims, M. D., Khanna, S., Feuerstadt, P., Louie, T. J., Kelly, C. R., Huang, E. S., Hohmann, E. L., Wang, E. E. L., Oneto, C., Cohen, S. H., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55758 · Cited by 83
Self-citationRokkas, T., Gisbert, J. P., Gasbarrini, A., Hold, G. L., Tilg, H., Malfertheiner, P., Mégraud, F., & O’Morain, C. A. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619854587 · Cited by 75
Wang, S., Ju, D., & Zeng, X. L. (2024) · Biomedicines · doi:10.3390/biomedicines12010194 · Cited by 72
Blount, K. F., Shannon, W. D., Deych, E., & Jones, C. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz095 · Cited by 66
Gonzales-Luna, A. J., Carlson, T. J., & Garey, K. W. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2223345 · Cited by 70
Kwak, S., Choi, J., Hink, T., Reske, K. A., Blount, K., Jones, C. R., Bost, M. H., Sun, X., Burnham, C. D., Dubberke, E. R., et al. (2020) · Microbiome · doi:10.1186/s40168-020-00907-9 · Cited by 66
Self-citationKhanna, S., Sims, M. D., Louie, T., Fischer, M., LaPlante, K. L., Allegretti, J. R., Hasson, B. R., Fonte, A. T., McChalicher, C. W. J., Ege, D. S., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11091234 · Cited by 61
Self-citationVaughn, B. P., Fischer, M., Kelly, C. R., Allegretti, J. R., Graiziger, C. T., Thomas, J., McClure, E. L., Kabage, A. J., & Khoruts, A. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.09.008 · Cited by 61
Khanna, S., Pardi, D. S., Jones, C. R., Shannon, W. D., Gonzalez, C., & Blount, K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1430 · Cited by 60
Self-citationFecal Microbiota Transplantation Across the Lifespan: Balancing Efficacy, Safety, and Innovation
Gulati, A., Nicholson, M. R., Khoruts, A., & Kahn, S. A. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002167 · Cited by 59
Mullane, K. M., Dubberke, E. R., & Practice, O. B. O. T. A. I. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13564 · Cited by 59
Self-citationDubberke, E. R., Orenstein, R., Khanna, S., Guthmueller, B., & Lee, C. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00744-3 · Cited by 57
Self-citationPoylin, V. Y., Hawkins, A. T., Bhama, A. R., Boutros, M., Lightner, A. L., Khanna, S., Paquette, I. M., & Feingold, D. L. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002047 · Cited by 50
Self-citationWilcox, M. H., McGovern, B., & Hecht, G. A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa114 · Cited by 49
Self-citationPorcari, S., Fusco, W. G., Spivak, I., Fiorani, M., Gasbarrini, A., Elinav, E., Cammarota, G., & Ianiro, G. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00357-6 · Cited by 47
Drekonja, D. M., Shaukat, A., Huang, Y., Zhang, J. H., Reinink, A. R., Nugent, S. M., Dominitz, J. A., Davis‐Karim, A., Gerding, D. N., & Kyriakides, T. C. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae467 · Cited by 48
Self-citationMcMillan, A. S., & Theriot, C. M. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2393766 · Cited by 44
Fecal microbiota transplantation: History, procedure and regulatory considerations
Thanush, D., & Venkatesh, M. P. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104204 · Cited by 44
Fecal microbiota-based treatment for recurrent Clostridioides difficile infection
Walter, J., & Shanahan, F. (2023) · Cell · doi:10.1016/j.cell.2023.02.034 · Cited by 42
Bascuñana, R. Á. P., Veses, V., & Sheth, C. C. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13486 · Cited by 41
Fecal microbiota transplantation for recurrent Clostridioides difficile , safety, and pitfalls
Sandhu, A., & Chopra, T. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211053105 · Cited by 41
The Route to Palatable Fecal Microbiota Transplantation
Fadda, H. M. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-1637-z · Cited by 37
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
Benech, N., Barbut, F., Fitzpatrick, F., Krůtová, M., Davies, K., Druart, C., Cordaillat‐Simmons, M., Heritage, J. C., Guery, B. P., & Kuijper, E. J. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.12.007 · Cited by 36
Integrative systems biology approaches for analyzing microbiome dysbiosis and species interactions
Rehman, S. S. U., Nasar, M. I., Mesquita, C. S., Khodor, S. A., Notebaart, R. A., Ott, S., Mundra, S., Arasardanam, R. P., Muhammad, K., & Alam, M. T. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf323 · Cited by 36
Emerging Options for the Prevention and Management of Clostridioides difficile Infection
Gonzales-Luna, A. J., Carlson, T. J., & Garey, K. W. (2023) · Drugs · doi:10.1007/s40265-022-01832-x · Cited by 36
Garey, K. W., Jo, J., Gonzales-Luna, A. J., Lapin, B. R., Deshpande, A., Wang, E., Hasson, B. R., Pham, S. V., Huang, S. P., Reese, P. R., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.53570 · Cited by 34
Self-citationFecal Microbiota Transplantation: Tales of Caution
Khanna, S., & Kraft, C. S. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1492 · Cited by 34
Self-citationWang, Y., Hunt, A., Danziger, L. H., & Drwiega, E. N. (2024) · Antibiotics · doi:10.3390/antibiotics13050436 · Cited by 32
Zhang, Y., Fleur, A. S., & Feng, H. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2052698 · Cited by 30
Kelly, C. R., Fischer, M., Grinspan, A. M., & Allegretti, J. R. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.06.034 · Cited by 29
Allegretti, J. R., Kelly, C. R., Louie, T., Fischer, M., Hota, S. S., Misra, B. K., van Hise, N., Yen, E. F., Bullock, J., Silverman, M., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.09.030 · Cited by 28
Self-citationManagement of Clostridioides difficile colitis: insights for the gastroenterologist
Saha, S., & Khanna, S. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819847651 · Cited by 27
Self-citationThe Integrative Human microbiome project: a mile stone in the understanding of the gut microbiome
Voth, E. R., & Khanna, S. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1780912 · Cited by 26
Self-citationMy Treatment Approach to Clostridioides difficile Infection
Khanna, S. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.03.033 · Cited by 25
Self-citationCausal role of the gut microbiome in certain human diseases: a narrative review
Prosty, C. J., Katergi, K., Papenburg, J., Lawandi, A., Lee, T. C., Shi, H., Burnham, P., Swem, L. R., Routy, B., Yansouni, C. P., et al. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100086 · Cited by 24
Aldriwesh, M. G., Alotibi, R. S., Alqurainy, N., Alrabiah, S., Arafah, A. M., Alghoribi, M. F., & Ajina, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2607076 · Cited by 24
Blount, K., Jones, C. R., Walsh, D. M., Gonzalez, C., & Shannon, W. D. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.781275 · Cited by 24
Voth, E. R., & Khanna, S. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1752192 · Cited by 23
Self-citationMicrobiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
Khanna, S. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13290 · Cited by 23
Self-citationKeller, J. J., Vehreschild, M. J. G. T., Hvas, C. L., Baunwall, S. M. D., Kupciskas, J., Link, A., Mulder, C. J. J., Goldenberg, S. D., Arasaradnam, R. P., Sokol, H., et al. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619887579 · Cited by 23
Araos, R., Battaglia, T., Ugalde, J. A., Rojas-Herrera, M., Blaser, M. J., & D’Agata, E. M. C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02260 · Cited by 22
Lim, E. C. N., & Lim, C. E. D. (2025) · Acta Microbiologica Hellenica · doi:10.3390/amh70030036 · Cited by 21
Papazyan, R., Ferdyan, N., Srinivasan, K., Gonzalez, C., Shannon, W. D., Blount, K., & Fuchs, B. C. (2023) · Microorganisms · doi:10.3390/microorganisms11010135 · Cited by 21
Emerging drugs for the treatment of clostridium difficile
Cammarota, G., Gallo, A., Ianiro, G., & Montalto, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591371 · Cited by 20
Antibiotic-Associated Diarrhea Beyond C. Difficile : A Scoping Review
Selvaraj, V., & Alsamman, M. A. (2022) · Journal of Brown Hospital Medicine · doi:10.56305/001c.39745 · Cited by 19
Orenstein, R. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00714-9 · Cited by 18
Self-citationThe human microbiota and infection prevention
Araos, R., & D’Agata, E. M. C. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.28 · Cited by 17
The potential of microbiome replacement therapies for Clostridium difficile infection
Buckley, A. M., Moura, I. B., & Wilcox, M. H. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000800 · Cited by 17
Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements
Mattana, M., Tomasello, R., Cammarata, C., Carlo, P. D., Fasciana, T., Giordano, G., Lucchesi, A., Siragusa, S. M., & Napolitano, M. (2022) · Microorganisms · doi:10.3390/microorganisms10081624 · Cited by 16
Reens, A. L., Cosetta, C. M., Saur, R., Trofimuk, O., Brooker, S. L., Lee, M. L., Sun, A. K., McKenzie, G. J., & Button, J. E. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2304160 · Cited by 15
A contemporary review of Clostridioides difficile infections in patients with haematologic diseases
Dutta, D., Jafri, F. M., STUHR, D., Knoll, B. M., & Lim, S. H. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13173 · Cited by 15
Chopra, T. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2171986 · Cited by 15
Alonso, C. D., Tillotson, G., Bidell, M. R., Guthmueller, B., Hoeyer, F., Fischer, M., & Dubberke, E. R. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf117 · Cited by 14
Self-citationDrug and gut microbe relationships: Moving beyond antibiotics
Kumbhare, S. V., Pedroso, I., Ugalde, J. A., Márquez‐Miranda, V., Sinha, R., & Almonacid, D. E. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103797 · Cited by 14
Lipids from gut microbiota: pursuing a personalized treatment
Carneiro, P. V., Montenegro, N. D. A., Lana, A. J., Amato, A. A., & Santos, G. M. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.06.001 · Cited by 13
Fighting against Clostridioides difficile infection: Current medications
Quan, M., Zhang, X., Fang, Q., Lv, X., Wang, X., & Zong, Z. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107198 · Cited by 13
Paschos, P., Ioakim, K., Malandris, K., Koukoufiki, A., Nayfeh, T., Akriviadis, E. A., Τσάπας, Α., & Bekiari, E. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102441 · Cited by 13
Live Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection
Pettit, N. N., Shaeer, K. M., & Chahine, E. B. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241239685 · Cited by 12
Weerakoon, S., Avula, S., Mandefro, B. T., Sundara, S. V., Lu, X., Busmail, H., & Malasevskaia, I. A. (2025) · Cureus · doi:10.7759/cureus.90737 · Cited by 12
Shaffer, S. R., Witt, J. C., Targownik, L. E., Kao, D. H., Lee, C., Smieliauskas, F., Rubin, D. T., Singh, H., & Bernstein, C. N. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.09.025 · Cited by 12
Self-citationMicrobiome therapeutics for the treatment of recurrent Clostridioides difficile infection
Bloom, P. P., & Young, V. B. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2154600 · Cited by 12
Khanna, S., Yoho, D. S., Handel, D. V., Clark, B. J., Awad, T., Guthmueller, B., Armandi, D., Knapple, W., Safdar, N., Baggott, B. B., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251339697 · Cited by 12
Self-citationProphage in Phage Manufacturing: Is the Risk Overrated Compared to Other Therapies or Food?
Gabard, J. (2020) · Antibiotics · doi:10.3390/antibiotics9080435 · Cited by 12
Elendu, C., Omeludike, E., Aregbesola, E. T., Mordi, P., Blewusi, G. S., Ogidan, A. O., Okeke, N. S., Obidigbo, B. T., Asini, A. O., Ubi, E. S., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003649 · Cited by 11
Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back
Miller, C. B., Bader, G. A., & Kay, C. (2026) · Current Gastroenterology Reports · doi:10.1007/s11894-025-01030-1 · Cited by 11
Designing bugs as drugs: exploiting the gut microbiome
Lamousé-Smith, E. S. N., Kelly, D., & de Cremoux, I. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00381.2019 · Cited by 11
Clostridioides difficile therapeutics: guidelines and beyond
Orenstein, R., & Patron, R. L. (2019) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936119868548 · Cited by 11
Self-citationRecent developments in the management of recurrent Clostridioides difficile infection
Mendo-López, R., Villafuerte-Gálvez, J., White, N., Mahoney, M. V. G., Kelly, C. P., & Alonso, C. D. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102108 · Cited by 11
Gao, Y., Li, H., Yang, H., Su, J., & Huang, L. (2019) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2019.1700905 · Cited by 11
Host microbiome-pathogen interactions in pediatric infections
Hurst, J. H., Heston, S. M., & Kelly, M. S. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000949 · Cited by 10
Contemporary Topics in Patient Safety - Volume 1
Stawicki, S. P., & Firstenberg, M. S. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87616 · Cited by 10
Jugan, M. C., KuKanich, K. S., & Freilich, L. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1050538 · Cited by 10
Blair, H. A. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-01023-y · Cited by 10
Wen, X., Liu, X., Wan, K., Liu, H., Zhang, C., Zhang, X., & Wen, Q. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1641564 · Cited by 9
Boyle, B. L., & Khanna, S. (2024) · Future Microbiology · doi:10.1080/17460913.2024.2364583 · Cited by 9
Self-citationGut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections
Lee, A., Yoo, J. S., & Yoon, E.-J. (2024) · Antibiotics · doi:10.3390/antibiotics13100995 · Cited by 9
Mehta, S. R., & Yen, E. F. (2020) · Translational research · doi:10.1016/j.trsl.2020.11.013 · Cited by 9
Hvas, C. L., Keller, J. J., Baunwall, S. M. D., Edwards, L. A., Ianiro, G., Kupčinskas, J., Link, A., Mullish, B. H., Satokari, R. M., Sokol, H., et al. (2023) · Lithuanian University of Health Sciences · doi:10.26355/mhd_202311_954 · Cited by 8
Safety and Potential Risks with Fecal Microbiota Transplantation
Gaonkar, P. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95907 · Cited by 8
Bernard, R., Hourigan, S. K., & Nicholson, M. R. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab056 · Cited by 8
Ke, S., Villafuerte-Gálvez, J., Sun, Z., Cao, Y., Pollock, N. R., Chen, X., Kelly, C. P., & Liu, Y. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae470 · Cited by 7
Vinterberg, J. E., Oddsdottir, J., Nye, M., & Pinton, P. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01105-y · Cited by 7
Keen, E. C., Tasoff, P., Hink, T., Reske, K. A., Burnham, C. D., Dantas, G. A., Kwon, J. H., & Dubberke, E. R. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa042 · Cited by 7
Self-citationDuo, H., Yang, Y., Zhang, G., Chen, Y., Cao, Y., Luo, L., Pan, H., & Ye, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1430724 · Cited by 7
Metadata
- Authors
- Dubberke, E. R., Lee, C. H., Orenstein, R., Khanna, S., Hecht, G., & Gerding, D. N.
- Affiliations
- Washington University in St. Louis (US)
- Island Health (CA)
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Loyola University Medical Center (US)
- Edward Hines, Jr. VA Hospital (US)
- Corresponding author
- Dubberke, Erik R
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-03-29
- Volume
- 67
- Issue
- 8
- Pages
- 1198-1204
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2795021885
- Cited by
- 140
- References
- 37
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 21 · 2023: 20 · 2022: 19 · 2021: 18 · 2020: 21 · 2019: 16 · 2018: 4
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Rebiotix Inc.
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- RBX2660, recurrent Clostridium difficile infection, microbiota-based therapy, fecal microbiota transplantation, dosing regimen, treatment efficacy, drug safety, adverse events
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Biological Therapy, Clostridium Infections, Diarrhea, Double-Blind Method, Enterocolitis, Pseudomembranous, Feces, Female, Humans, Male, Middle Aged, Recurrence, Clostridioides difficile, Treatment Outcome, Young Adult, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.